These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8353403)

  • 21. Incidence and reactivity patterns of skeletal and heart (SH) reactive autoantibodies in the sera of patients with myasthenia gravis.
    Connor RI; Lefvert AK; Benes SC; Lang RW
    J Neuroimmunol; 1990 Feb; 26(2):147-57. PubMed ID: 2298883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are linear AChR epitopes the real culprit in ocular myasthenia gravis?
    Wu X; Tüzün E
    Med Hypotheses; 2017 Feb; 99():26-28. PubMed ID: 28110692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
    Isshiki Y; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.
    Aguirre F; Villa AM
    Eur Neurol; 2018; 79(3-4):113-117. PubMed ID: 29428956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
    Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
    Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
    Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
    Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis.
    Somnier FE; Skeie GO; Aarli JA; Trojaborg W
    Eur J Neurol; 1999 Sep; 6(5):555-63. PubMed ID: 10457388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
    Allen JA; Scala S; Jones HR
    Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathologic study of extraocular muscles in thyroid-associated ophthalmopathy coexisting with ocular myasthenia gravis: a case report.
    Ma R; Cheng Y; Gan L; Zhou X; Qian J
    BMC Ophthalmol; 2020 Apr; 20(1):166. PubMed ID: 32321476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroid.
    Zhang ZG; Dong Q; Rodien P; Alcalde L; Bernard N; Boucher A; Salvi M; Arthurs B; Vassart GM; Ludgate M
    Autoimmunity; 1992; 13(2):151-7. PubMed ID: 1467436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis.
    Velonakis G; Papadopoulos VE; Karavasilis E; Filippiadis DK; Zouvelou V
    Neuroradiology; 2021 Sep; 63(9):1531-1538. PubMed ID: 34232334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive treatment of ocular myasthenia gravis.
    Tackenberg B; Hemmer B; Oertel WH; Sommer N
    BioDrugs; 2001; 15(6):369-78. PubMed ID: 11520248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers.
    Oda K
    Ann N Y Acad Sci; 1993 Jun; 681():238-55. PubMed ID: 8357165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.
    Zhang M; Guo J; Li H; Zhou Y; Tian F; Gong L; Wang X; Li Z; Zhang W
    J Mol Neurosci; 2013 Jun; 50(2):317-23. PubMed ID: 23397576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of patients with ocular myasthenia gravis - A case series.
    Karni A; Asmail A; Drory VE; Kolb H; Kesler A
    eNeurologicalSci; 2016 Sep; 4():30-33. PubMed ID: 29430546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis.
    Wang ZY; Diethelm-Okita B; Okita DK; Kaminski HJ; Howard JF; Conti-Fine BM
    J Neuroimmunol; 2000 Aug; 108(1-2):29-39. PubMed ID: 10900334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.